CLAIMS

1. A method for evaluating the risk of occurrence of a cancer in a human subject who has not been previously diagnosed with cancer, said method comprising the steps of:

a) determining the level of progastrin in a sample of said subject;

b) determining the risk that said subject will develop a cancer based on the level of step a),

wherein the determination of step a) includes:

- contacting said sample with at least the monoclonal antibody Mab14 produced by the hybridoma deposited at the CNCM, Institut Pasteur, 25-28 rue du Docteur Roux, 75724 Paris CEDEX 15, France, on 27 December 2016, under reference I-5158,

- and measuring the binding of said monoclonal antibody to progastrin.

2. The method of claim 1, wherein the determination of step a) includes contacting said sample with at least one other progastrin-binding molecule, said progastrin-binding molecule binding to a part of progastrin which is not boundby Mab14.

3. The method of claim 2, wherein said other progastrin-binding molecule is an anti-progastrin antibody, or an antigen-binding fragment thereof.

4. The method of claim 3, wherein said antibody binds the N-terminus of progastrin.

5. The method of any one of claims 3 or 4, wherein said antibody is a monoclonal antibody or a polyclonal antibody.

6. The method of claim 3 to 5, wherein said monoclonal antibody is selected in the group consisting of:

- A monoclonal antibody mAb13 comprising a heavy chain comprising the following three CRDs, CDR-H1, CDR-H2 and CDR-H3 of amino acid sequences SEQ ID N°4, 5 and 6, respectively, and a light chain comprising the following three CDRs, CDR-L1, CDR-L2 and CDR-L3 of amino acid sequences SEQ ID N°7, 8 and 9, respectively,

- A monoclonal antibody mAb4 comprising a heavy chain comprising the following three CDRs CDR-H1, CDR-H2 and CDR-H3 of amino acid sequences SEQ ID N°10, 11 and 12, respectively, and a light chain comprising the following three CDRs, CDR-L1, CDR-L2 and CDR-L3 of amino acid sequences SEQ ID N°13, 14 and 15, respectively,

- A monoclonal antibody mAb 16 comprising a heavy chain comprising the following three CDRs, CDR-H1, CDR-H2 and CDR-H3 of amino acid sequences SEQ ID N°16, 17 and 18, respectively, and a light chain comprising the following three CDRs, CDR-L1, CDR-L2 and CDR-L3 of amino acid sequences SEQ ID N°19, 20 and 21, respectively, and

- A monoclonal antibody mAb19 comprising a heavy chain comprising the following three CDRs, CDR-H1, CDR-H2 and CDR-H3 of amino acid sequences SEQ ID N°22, 23 and 24, respectively, and a light chain comprising the following three CDRs, CDR-L1, CDR-L2 and CDR-L3 of amino acid sequences SEQ ID N°25, 26 and 27, respectively

7. The method of any one of claims 1 to 6, wherein the monoclonal antibody Mab14 is bound to an insoluble or partly soluble carrier and the second antibody is labelled with a detectable moiety.

8. The method of any one of claims 3 to 7, wherein the level of progastrin is determined in step a) with an ELISA assay.

9. The method of any one of claim 1 to 8, wherein said biological sample is chosen among: blood, serum and plasma.

10. The method of any one of claims 1 to 9, wherein risk of developing cancer in said subject is determined by comparing the concentration of step a) with a reference level.

11. The method of claim 10, wherein said reference level is 0 pM

12. A kit comprising at least the monoclonal antibody Mab14 produced by the hybridoma deposited at the CNCM, Institut Pasteur, 25-28 rue du Docteur Roux, 75724 Paris CEDEX 15, France, on 27 December 2016, under reference I-5158 for use in the method of any one of claims 1 to 11.

13. The kit of claim 12, comprising:

-a first anti-progastrin antibody, wherein said first anti-progastrin antibody is the monoclonal antibody mAb14 produced by the hybridoma deposited at the CNCM, Institut Pasteur, 25-28 rue du Docteur Roux, 75724 Paris CEDEX 15, France, on 27 December 2016, under reference I-5158; and

- a second anti-progastrin antibody, wherein said second anti-progastrin antibody is:

- a polyclonal antibody binding the N-terminus of progastrin or
- a monoclonal antibody selected from the group consisting of:
- a monoclonal antibody mAb3 comprising a heavy chain comprising the following three CDRs, CDR-H1, CDR-H2 and CDR-H3 of amino acid sequences SEQ ID N°4, 5 and 6, respectively, and a light chain comprising the following three CDRs, CDR-L1, CDR-L2 and CDR-L3 of amino acid sequences SEQ ID N°7, 8 and 9, respectively,
- a monoclonal antibody mAb4 comprising a heavy chain comprising the following three CDRs,CDR-H1, CDR-H2 and CDR-H3 of amino acid sequences SEQ ID N°10, 11 and 12, respectively, and a light chain comprising the following three CDRs, CDR-L1, CDR-L2 and CDR-L3 of amino acid sequences SEQ ID N°13, 14 and 15, respectively,
- a monoclonal antibody mAb16 comprising a heavy chain comprising the following three CDRs, CDR-H1, CDR-H2 and CDR-H3 of amino acid sequences SEQ ID N°16, 17 and 18, respectively, and a light chain comprising the following three CDRs, CDR-L1, CDR-L2 and CDR-L3 of amino acid sequences SEQ ID N°19, 20 and 21, respectively, and
- a monoclonal antibody mAb19 comprising a heavy chain comprising the following three CDRs,CDR-H1, CDR-H2 and CDR-H3 of amino acid sequences SEQ ID N°22, 23 and 24, respectively, and a light chain comprising the following three CDRs, CDR-L1, CDR-L2 and CDR-L3 of amino acid sequences SEQ ID N°25, 26 and 27, respectively .

14. A product/computer program containing a set of instructions characteristic of implementation of the method of any one of claims 1 to 11.

15. A processing system including a computation unit and an input interface, said system including means for implementing the method of any one of claims 1 to 11.